The biotechnology industry is currently on the high demand, especially with increasing number of new diseases every year. Biotechnology companies discover, develop and promote their products that can overcome the health issues. Many companies are in a constant global fighting and time to come up with best and effective solution to defeat the coronavirus and other important diseases. Regeneron Pharmaceuticals, Illumina and Vertex Pharmaceuticals Incorporated are expected promising stocks in biotechnology industry.
Regeneron Pharmaceuticals Inc, NASDAQ: REGN, Inc. discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. They originally focused on neurotrophic factors, it branched out into the study of both cytokine and tyrosine kinase receptors. Regeneron Pharmaceuticals Inc was founded on 1988. Regeneron Pharmaceuticals Inc has a market cap of $64.92 billion with the trailing twelve months (TTM) revenue of $8.32 billion that ended Mar 30, 2020. Moreover, REGN has a gross profit (TTM) 4.04 billion. Regeneron Pharmaceuticals Inc closed at $644.06 with a profit of $11.85 (+1.87%). The forecast analysis expects gain for REGN in the duration of 12-month investment with a high price target of $1009.278. For the long-term investment of 5-year, REGN revenue is expected to rise around +17.79% and target price to be at $3620.027.
Illumina, Inc. NASDAQ: ILMN, was Founded on 1998. The company is focusing on genetic variation and biological function, providing a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies. Illumina has a market cap of $55.25 billion with the trailing twelve months (TTM) revenue of $3.56 billion that ended Mar 28, 2020. Illumina gain profit of $7.76 (+2.06%), and closed at $383.64. According to the forecast analyst of ILMN stock, growth is expected about 31.343% and hit the price of $648.715. For the forecast analysis, long-term investment of 5 years Illumina is expected to reach the target of $2192.882.
Vertex Pharmaceuticals Incorporated, NASDAQ: VRTX, is an American biopharmaceutical company founded in 1989. The company discover, develops, and commercializes new products over 30 years. Vertex Pharmaceuticals develops drugs for the treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease, and neurological disorders. The market cap of Vertex Pharmaceuticals Incorporated is $76.52 billion. The revenue (TTM) of VRTX is $4.82 billion, with a gross profit (TTM) of $1.86 billion. VRTX operating cash flow (TTM) of $2.06 billion, with a levered free cash flow (TTM) $1.33 billion. Vertex Pharmaceuticals Incorporated closed at $294.53 with a gain of $3.97 (+1.37%). The 25 analysts offering 12-month price forecasts for VRTX have a median target of $309, with a high estimate of $340 and a low estimate of $245. The median estimate represents a 4.91% increase from the closing price. For the long-term 5-year investment, VRTX is expected to gain about +25.74%.
© 2000-2021. All rights reserved.
This site is managed by Teletrade D.J. Limited 20599 IBC 2012 (First Floor, First St. Vincent Bank Ltd Building, James Street, Kingstown, St. Vincent and the Grenadines).
The information on this website is for informational purposes only and does not constitute any investment advice.
Making transactions on financial markets with marginal financial instruments opens up wide possibilities and allows investors who are willing to take risks to earn high profits, carrying a potentially high risk of losses at the same time. Therefore you should responsibly approach the issue of choosing the appropriate investment strategy, taking the available resources into account, before starting trading.
Use of the information: full or partial use of materials from this website must always be referenced to TeleTrade as the source of information. Use of the materials on the Internet must be accompanied by a hyperlink to teletrade.org. Automatic import of materials and information from this website is prohibited.
Please contact our PR department if you have any questions or need assistance at email@example.com.